Outlook Therapeutics (OTLK) Retained Earnings (2015 - 2026)
Outlook Therapeutics (OTLK) reported Retained Earnings of -$633.2 million for Q1 2026, down 10.65% year-over-year from -$708.7 million in Q1 2025, and down 0.71% quarter-over-quarter from -$628.8 million in Q4 2025.
Outlook Therapeutics (OTLK) Retained Earnings (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Retained Earnings data on file, last reported at -$633.2 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$633.2 million, down 10.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$633.2 million (down 10.65% YoY), and the FY2025 annual result was -$605.7 million, down 11.49% from the prior year.
- Retained Earnings slipped to -$633.2 million in Q1 2026 per OTLK's latest filing, from -$628.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$377.1 million in Q1 2022 and troughed at -$633.2 million in Q1 2026.
- A 5-year average of -$511.1 million and a median of -$525.9 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings tumbled 36.65% in 2024, then advanced 3.56% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$427.6 million in 2022, then retreated by 12.04% to -$479.1 million in 2023, then dropped by 9.77% to -$525.9 million in 2024, then slipped by 19.56% to -$628.8 million in 2025, then fell by 0.71% to -$633.2 million in 2026.
- Business Quant data shows OTLK's Retained Earnings at -$633.2 million in Q1 2026, -$628.8 million in Q4 2025, and -$605.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -838.07 Mn |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | -633.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -633.22 Mn |
| Dec 31, 2025 | -628.77 Mn |
| Sep 30, 2025 | -605.71 Mn |
| Jun 30, 2025 | -592.42 Mn |
| Mar 31, 2025 | -572.26 Mn |
| Dec 31, 2024 | -525.91 Mn |
| Sep 30, 2024 | -543.28 Mn |
| Jun 30, 2024 | -548.98 Mn |
| Mar 31, 2024 | -593.39 Mn |
| Dec 31, 2023 | -479.10 Mn |
| Sep 30, 2023 | -467.92 Mn |
| Jun 30, 2023 | -454.93 Mn |
| Mar 31, 2023 | -434.25 Mn |
| Dec 31, 2022 | -427.60 Mn |
| Sep 30, 2022 | -408.94 Mn |
| Jun 30, 2022 | -394.59 Mn |
| Mar 31, 2022 | -377.05 Mn |
| Dec 31, 2021 | -357.35 Mn |
| Sep 30, 2021 | -342.88 Mn |
| Jun 30, 2021 | -329.48 Mn |